Acumen Joins Neurotechnology Industry Organization.SOUTH SAN FRANCISCO South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. , Calif. -- Acumen Pharmaceuticals, a leading pre-clinical biotech company in Alzheimer's therapeutics, today announced that it has joined the Neurotechnology Industry Organization The Neurotechnology Industry Organization (NIO) is a San Francisco, California based non-profit trade association that represents a broad spectrum of companies involved in neuroscience, brain research centers, and advocacy groups from around the globe. (NIO NIO In currencies, this is the abbreviation for the Nicaraguan Coroba Oro. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. ) as a charter member. As a part of the newly formed NIO, the company will work along side other leading pharmaceutical, medical device and diagnostic companies as well as major academic brain research centers and patient advocacy Patient advocacy refers to speaking on behalf of a patient in order to protect their rights and help them obtain needed information and services. The role of patient advocate is frequently assumed by nurses, social workers, and other healthcare providers. groups to accelerate the development of treatments and cures for brain and nervous system diseases. "The support of Acumen and our other founding members was crucial in launching NIO," said Zack Lynch, founder and executive director of the Neurotechnology Industry Organization. "Our association is backed by leaders in the industry who will make it possible for us to educate governments, patients and the public about our role in the treatments that delay, prevent and cure chronic neurological diseases and psychiatric illnesses." "Acumen recognizes the need for an advocacy group that links those involved in delivering significantly better therapies for brain and nervous system illnesses," said David Summa, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Acumen. "NIO provides an ideal forum to identify and address the barriers that slow or limit advances in our field, and work collaboratively with others who also want to speed the development process." In addition to developing pharmaceuticals, the neurotechnology industry includes medical devices and diagnostic surgical equipment for Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. , addiction, anxiety, depression, epilepsy, hearing loss, insomnia, multiple sclerosis, obesity, pain, Parkinson's disease Parkinson's disease or Parkinsonism, degenerative brain disorder first described by the English surgeon James Parkinson in 1817. When there is no known cause, the disease usually appears after age 40 and is referred to as Parkinson's disease. , schizophrenia, stroke and other brain-related illnesses. In 2005, neurotechnology companies generated more than $110 billion in revenue. "Acumen is a forward thinking company. They typify the recent and exciting developments in the Alzheimer's field. Their founders identified what most today agree is the causative agent in the disease, and they are focused on developing a cure. This offers hope to both patients and their caregivers," said Zach Lynch. About Acumen Acumen Pharmaceuticals Inc. (www.acumenpharm.com) is a venture-backed, pre-clinical biotech company focused on developing the first effective therapeutics and diagnostics for Alzheimer's disease and other memory-related disorders. Founded in 1996, Acumen owns or has licensed the critical patents underlying the ADDL ADDL Additional ADDL Animal Disease Diagnostic Laboratory (University of the Philippines, College of Veterinary Medicine) ADDL American Double Dutch League ADDL Amyloid Beta-Derived Diffusible Ligand mechanism now widely believed to cause Alzheimer's disease. In addition to ELISA-based diagnostic, Acumen has several therapeutic approaches to stop ADDL-related diseases. NeuroVentures LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control has made a seed investment in the company. About the Neurotechnology Industry Organization The Neurotechnology Industry Organization (NIO) is a non-profit trade association that represents a broad spectrum of companies involved in neurotechnology (drugs, devices and diagnostics), neuroscience research centers and brain disease advocacy groups across the United States and the world. NIO's mission is to accelerate cures for brain and nervous system diseases by promoting the neurotechnology industry's progress, advocating the industry's position to government officials and providing business development services to its members. For information on the Neurotechnology Industry Organization, please visit www.neurotechindustry.org. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion